Sangamo Therapeutics (SGMOQ) Accumulated Expenses (2010 - 2025)

Sangamo Therapeutics' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $9.4 million for Q4 2025.

• On a quarterly basis, Accumulated Expenses fell 35.42% year-over-year to $9.4 million in Q4 2025; TTM through Dec 2025 was $9.4 million, a 35.42% decrease from a year earlier, with the FY2025 full-year figure at $9.4 million, down 35.42% from the prior year.
• Accumulated Expenses eased to $9.4 million in Q4 2025 per SGMOQ's latest filing, from $17.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $23.6 million in Q4 2023 and bottomed at $6.3 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $14.7 million (2021), against an average of $14.7 million.
• Across the five-year window, Accumulated Expenses jumped 85.76% in 2022 and sank 51.35% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $11.6 million in 2021, then soared by 85.76% to $21.5 million in 2022, then advanced by 9.52% to $23.6 million in 2023, then plunged by 38.15% to $14.6 million in 2024, then tumbled by 35.42% to $9.4 million in 2025.
• Per Business Quant, the three latest SGMOQ Accumulated Expenses figures stand at $9.4 million (Q4 2025), $17.1 million (Q3 2025), and $15.4 million (Q2 2025).